Conflict of Interest
Dr Therriault has served as a paid consultant for the Neurotorium educational platform and for Alzheon. Dr Ashton received payment for lectures from Biogen, BioArtic, Eli-Lily, and Quanterix. Dr. Karikari reported receiving grants from the National Institutes of Health and receiving personal fees from the University of Wisconsin–Madison and the University of Pennsylvania outside the submitted work; in addition, Dr Karikari had a patent for WO2020193500A1 issued. Dr Zetterberg reported receiving personal fees from Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; receiving personal fees for sponsored lectures from Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche outside the submitted work; and being a cofounder of Brain Biomarker Solutions, which is a part of the GU Ventures Incubator Program outside submitted work. Dr Blennow reported having served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Eli Lilly and Co, Moleac Pte Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; having served on data monitoring committees for Julius Clinical and Novartis; having given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and being a cofounder of Brain Biomarker Solutions, which is a part of the GU Ventures Incubator Program, outside the submitted work. Dr Zimmer served in the SAB of Novo Nordisk, serves on SAB of Next Innovative Therapeutics (Nintx) and serves on the SAB and is a Co-founder of MASIMA. Dr Rosa-Neto served in the SAB of Novo Nordisk, Eisai, and Ely Lilly and as a Consultant in Eisai and Cerveau radiopharmaceuticals. No other disclosures were reported.
Acknowledgments
Dr. Pascoal is supported by the NIA (5R01AG075336, 5R01AG073267). Dr. Rohden receives financial support from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (102380/2022-8). Dr. Ferreira is supported by the Alzheimer’s Association (AARFD-22-923814). Dr. Bellaver is supported by the Alzheimer’s Association (grant No. AARFD-22-974627) and the National Institute of Aging (5 P01 AG025204-17). Dr. Povala is supported by the Alzheimer’s Association (24AARFD-1243899). Ms. Soares has received funding from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) [88887.696202/2022-00] and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) [141357/2020-7]. Dr. Bauer-Negrini is supported by the Alzheimer’s Association (AARFD-23-1150249). Dr. Schaffer Aguzzoli is supported by the Global Brain Health Institute, Alzheimer’s Association, and Alzheimer’s Society (grant No. GBHI ALZ UK-23-971089), and Alzheimer’s Association (grant No. 24AACSF-1200375). Mr. Ferrari-Souza is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (No. 200691/2021-0). Dr. Therriault is funded by the Colin J Adair Family Foundation Scholarship. Dr. Karikari receives financial support from the NIH (R01 AG083874 and U24 AG082930), Swedish Research Council (Vetenskåpradet; #2021–03244), Alzheimer’s Association (#AARF21-850325), Swedish Alzheimer Foundation (Alzheimerfonden), Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen, Emil och Wera Cornells stiftelsen. Dr. Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356; #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Dr. Blennow is supported by the Swedish Research Council (2017 − 00915), the Alzheimer Drug Discovery Foundation (RDAPB-201809-2016615), the Swedish Alzheimer Foundation (AF-742881), Hjärnfonden (FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the NIH (1R01AG068398-01), and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495). Dr. Zimmer receives financial support from CNPq [312410/20182; 435642/2018-9; 312306/2021-0; 409066/2022-2], ARD/FAPERGS [21/2551-0000673-0], AA [AARGD-21-850670], CNPQ/FAPERGS/PRONEX [16/2551-0000475-7], the Brazilian National Institute of Science and Technology in Excitotoxicity and Neuroprotection [465671/2014-4], Instituto Serrapilheira [Serra-1912-31365], and National Academy of Neuropsychology [ALZ-NAN-22-928381]. Dr. Souza is supported by CNPQ/INCT [465671/2014-4], CNPQ/ FAPERGS/PRONEX [16/2551- 0000475-7], and FAPERGS [19/2551-0000700-0]. Dr. Rosa-Neto is funded by Fonds de Recherche du Québec–Santé (Chercheur Boursier, PR-N and 2020-VICO-279314) and CIHR-CCNA. TRIAD cohort was supported by grants MOP-11-51-31 and RFN 152985, 159815, 162303 from the Canadian Institutes of Health Research (CIHR); MOP-11-51-31 from the Canadian Consortium of Neurodegeneration and Aging (CCNA); the Weston Brain Institute; and grants NIRG-12-92-92090 and NIRP-12-259245 from the Alzheimer Association.